Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on ...

Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, ...

Moderna Inc. continues to push its cost-savings work as Covid-19 vaccination rates decline. The company's third-quarter 2025 ...